MUC1 and neoplasm: The 21-mer SP domain of MUC1 (MUC1 SP), herein the MUC1-SP-L or VXL100 peptide or the formulated therapeutic vaccine, ImMucin [28], is processed and presented in association with multiple MHC class I and II on the cell surface of both antigen presenting cells and various MUC1-positive tumor cells, which can generate robust T-cell immunity against MUC1-positive tumors [28].